[go: up one dir, main page]

UY24389A1 - Composición farmacéutica para el tratamiento de carcinoma de epitelio plano - Google Patents

Composición farmacéutica para el tratamiento de carcinoma de epitelio plano

Info

Publication number
UY24389A1
UY24389A1 UY24389A UY24389A UY24389A1 UY 24389 A1 UY24389 A1 UY 24389A1 UY 24389 A UY24389 A UY 24389A UY 24389 A UY24389 A UY 24389A UY 24389 A1 UY24389 A1 UY 24389A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical composition
treatment
flat epithelium
antibody
epithelium carcinoma
Prior art date
Application number
UY24389A
Other languages
English (en)
Inventor
Marlies Sproll
Erik Patzelt
Elingborg Ostermann
Guenther Adolf
Karl-Heinz Heider
Original Assignee
Karlsruhe Forschzent
Boheringer Ingelheim Internat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545472A external-priority patent/DE19545472A1/de
Application filed by Karlsruhe Forschzent, Boheringer Ingelheim Internat filed Critical Karlsruhe Forschzent
Publication of UY24389A1 publication Critical patent/UY24389A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere al empleo de una molécula de anticuerpo que se une específicamente a la secuencia de aminoácidos WFGNRWHEGYR del exón variable v6 del gen CD44, para la producción de una composición farmacéutica para la terapia de carcinomas del epitelio plano. En particular, se caracteriza porque la molécula de anticuerpo es el anticuerpo monoclonal BIWA-1 (VFF-18) que se forma por la línea de células hibridomas con el número de depósito DSM ACC2174, o un derivado de este anticuerpo.
UY24389A 1995-12-06 1996-12-03 Composición farmacéutica para el tratamiento de carcinoma de epitelio plano UY24389A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19545472A DE19545472A1 (de) 1995-12-06 1995-12-06 Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19615074 1996-04-17

Publications (1)

Publication Number Publication Date
UY24389A1 true UY24389A1 (es) 2001-10-25

Family

ID=26020988

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24389A UY24389A1 (es) 1995-12-06 1996-12-03 Composición farmacéutica para el tratamiento de carcinoma de epitelio plano

Country Status (25)

Country Link
EP (1) EP0865609B1 (es)
JP (1) JP2000502067A (es)
KR (1) KR100473824B1 (es)
CN (1) CN1151377C (es)
AR (1) AR004360A1 (es)
AT (1) ATE235056T1 (es)
AU (1) AU726704B2 (es)
BG (1) BG62985B1 (es)
BR (1) BR9611901A (es)
CA (1) CA2239709A1 (es)
CO (1) CO4520233A1 (es)
CZ (1) CZ174198A3 (es)
DE (1) DE59610248D1 (es)
DK (1) DK0865609T3 (es)
EE (1) EE03783B1 (es)
ES (1) ES2190484T3 (es)
MX (1) MX9804459A (es)
NO (1) NO319903B1 (es)
NZ (1) NZ324314A (es)
PL (1) PL184521B1 (es)
PT (1) PT865609E (es)
SK (1) SK284378B6 (es)
TR (1) TR199801027T2 (es)
UY (1) UY24389A1 (es)
WO (1) WO1997021104A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
BR0210905A (pt) * 2001-05-18 2004-06-08 Boehringer Ingelheim Int Anticorpos especìficos para cd44v6
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
AU2011212485B2 (en) * 2010-02-04 2014-04-17 University Of Miami A monoclonal antibody to CD44 for use in the treatment of head and neck squamous cell carcinoma
US9218450B2 (en) 2012-11-29 2015-12-22 Roche Molecular Systems, Inc. Accurate and fast mapping of reads to genome
EP3755717A4 (en) * 2018-02-22 2022-01-26 Multitude Inc. THERAPEUTIC ANTIBODIES AND ASSOCIATED USES
KR20250017214A (ko) 2022-05-25 2025-02-04 아키람 테라퓨틱스 에이비 항cd44v6 항체 및 이들의 cd44v6 과발현 암 치료의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69406664T2 (de) * 1993-06-18 1998-06-04 Biotie Therapies Oy Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6
EP0767378A1 (de) * 1993-06-22 1997-04-09 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Diagnose und Analyse von Magenkarzinomen
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти

Also Published As

Publication number Publication date
EP0865609B1 (de) 2003-03-19
AU726704B2 (en) 2000-11-16
BR9611901A (pt) 1999-03-02
NZ324314A (en) 2000-02-28
NO982588D0 (no) 1998-06-05
MX9804459A (es) 1998-09-30
KR19990071952A (ko) 1999-09-27
JP2000502067A (ja) 2000-02-22
DE59610248D1 (de) 2003-04-24
DK0865609T3 (da) 2003-06-23
PL327066A1 (en) 1998-11-23
CO4520233A1 (es) 1997-10-15
AU1177397A (en) 1997-06-27
CA2239709A1 (en) 1997-06-12
BG62985B1 (bg) 2000-12-29
NO319903B1 (no) 2005-09-26
EE9800164A (et) 1998-12-15
WO1997021104A1 (de) 1997-06-12
ES2190484T3 (es) 2003-08-01
CZ174198A3 (cs) 1999-02-17
SK284378B6 (sk) 2005-02-04
PT865609E (pt) 2003-08-29
SK73698A3 (en) 1999-01-11
AR004360A1 (es) 1998-11-04
ATE235056T1 (de) 2003-04-15
EE03783B1 (et) 2002-06-17
KR100473824B1 (ko) 2005-09-30
PL184521B1 (pl) 2002-11-29
NO982588L (no) 1998-08-05
CN1207811A (zh) 1999-02-10
BG102513A (en) 1999-02-26
CN1151377C (zh) 2004-05-26
TR199801027T2 (xx) 1998-10-21
EP0865609A1 (de) 1998-09-23
HK1011560A1 (en) 1999-07-16

Similar Documents

Publication Publication Date Title
CA2541438C (en) The modulation of hyaluronan synthesis and degradation in the treatment of disease
UY24389A1 (es) Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
MX2023004349A (es) Anticuerpos monoclonales anti-ccr8 y sus usos.
BR0110927A (pt) Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
JP2019110906A5 (es)
BRPI0409879A (pt) composições e métodos para imunoterapia especìfica wt1
AR021849A1 (es) Composiciones y metodos para la inmunoterapia especifica de wt1
PE20230415A1 (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SINDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
JP2016116536A5 (es)
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
JP2018193386A5 (es)
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
CY1109421T1 (el) ΔΟΣΕΙΣ ΓΙΑ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
ATE335072T1 (de) Methoden für inhibition der cd14-abhängigen zellaktivierung
RU2010119521A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
RU2009117299A (ru) Применение моноклональных антител, специфичных к о-ацетилированной форме ганглиозида gd2, для лечения некоторых форм рака
PE20110822A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamida
UA86768C2 (ru) ХИМЕРНОЕ МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, ПОЛУЧЕННОЕ ИЗ МЫШИНОГО АНТИИДИОТИПИЧНОГО МОНОКЛОНАЛЬНОГО АНТИТЕЛА 1Е10, КОТОРОЕ РАСПОЗНАЕТ МЫШИНОЕ MAbР3
Shohet et al. Identification of a major binding site for complement C3 on the IgG1 heavy chain.
BR112022009570A2 (pt) Anticorpo anti-¿v¿6 isolado ou fragmento de ligação ao antígeno, conjugado anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-¿v¿6 ou fragmento de ligação ao antígeno, para produção de um conjugado anticorpo anti-¿v¿6-fármaco e para tratamento de câncer em um indivíduo, e, composição farmacêutica
RU2017134043A (ru) Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью
Koro et al. Carbamylation of immunoglobulin abrogates activation of the classical complement pathway
Myers et al. Type XIX collagen purified from human umbilical cord is characterized by multiple sharp kinks delineating collagenous subdomains and by intermolecular aggregates via globular, disulfide-linked, and heparin-binding amino termini
AR123537A1 (es) Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca
MX2024014979A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20161203